| Literature DB >> 28890434 |
Antoni Torres1,2, Michael S Niederman3,2, Jean Chastre4, Santiago Ewig5, Patricia Fernandez-Vandellos6, Hakan Hanberger7, Marin Kollef8, Gianluigi Li Bassi9, Carlos M Luna10, Ignacio Martin-Loeches11, J Artur Paiva12, Robert C Read13, David Rigau14, Jean François Timsit15, Tobias Welte16, Richard Wunderink17.
Abstract
The most recent European guidelines and task force reports on hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) were published almost 10 years ago. Since then, further randomised clinical trials of HAP and VAP have been conducted and new information has become available. Studies of epidemiology, diagnosis, empiric treatment, response to treatment, new antibiotics or new forms of antibiotic administration and disease prevention have changed old paradigms. In addition, important differences between approaches in Europe and the USA have become apparent.The European Respiratory Society launched a project to develop new international guidelines for HAP and VAP. Other European societies, including the European Society of Intensive Care Medicine and the European Society of Clinical Microbiology and Infectious Diseases, were invited to participate and appointed their representatives. The Latin American Thoracic Association was also invited.A total of 15 experts and two methodologists made up the panel. Three experts from the USA were also invited (Michael S. Niederman, Marin Kollef and Richard Wunderink).Applying the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) methodology, the panel selected seven PICO (population-intervention-comparison-outcome) questions that generated a series of recommendations for HAP/VAP diagnosis, treatment and prevention.Entities:
Mesh:
Year: 2017 PMID: 28890434 DOI: 10.1183/13993003.00582-2017
Source DB: PubMed Journal: Eur Respir J ISSN: 0903-1936 Impact factor: 16.671